These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 10736276)
1. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Cotter G; Kaluski E; Blatt A; Milovanov O; Moshkovitz Y; Zaidenstein R; Salah A; Alon D; Michovitz Y; Metzger M; Vered Z; Golik A Circulation; 2000 Mar; 101(12):1358-61. PubMed ID: 10736276 [TBL] [Abstract][Full Text] [Related]
2. Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Dzavík V; Cotter G; Reynolds HR; Alexander JH; Ramanathan K; Stebbins AL; Hathaway D; Farkouh ME; Ohman EM; Baran DA; Prondzinsky R; Panza JA; Cantor WJ; Vered Z; Buller CE; Kleiman NS; Webb JG; Holmes DR; Parrillo JE; Hazen SL; Gross SS; Harrington RA; Hochman JS; Eur Heart J; 2007 May; 28(9):1109-16. PubMed ID: 17459901 [TBL] [Abstract][Full Text] [Related]
3. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Cotter G; Kaluski E; Milo O; Blatt A; Salah A; Hendler A; Krakover R; Golick A; Vered Z Eur Heart J; 2003 Jul; 24(14):1287-95. PubMed ID: 12871685 [TBL] [Abstract][Full Text] [Related]
4. Tissue oxygenation and hemodynamic response to NO synthase inhibition in septic shock. Broccard A; Hurni JM; Eckert P; Liaudet L; Schaller MD; Lazor R; Perret C; Feihl F Shock; 2000 Jul; 14(1):35-40. PubMed ID: 10909891 [TBL] [Abstract][Full Text] [Related]
5. Expert opinion on tilarginine in the treatment of shock. Howes LG; Brillante DG Expert Opin Investig Drugs; 2008 Oct; 17(10):1573-80. PubMed ID: 18808317 [TBL] [Abstract][Full Text] [Related]
6. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Petros A; Lamb G; Leone A; Moncada S; Bennett D; Vallance P Cardiovasc Res; 1994 Jan; 28(1):34-9. PubMed ID: 7509259 [TBL] [Abstract][Full Text] [Related]
7. Postsynaptic α1-Adrenergic Vasoconstriction Is Impaired in Young Patients With Vasovagal Syncope and Is Corrected by Nitric Oxide Synthase Inhibition. Stewart JM; Suggs M; Merchant S; Sutton R; Terilli C; Visintainer P; Medow MS Circ Arrhythm Electrophysiol; 2016 Aug; 9(8):. PubMed ID: 27444639 [TBL] [Abstract][Full Text] [Related]
8. In vivo quantification of endotoxin-induced nitric oxide production in pigs from Na15NO3-infusion. Santak B; Radermacher P; Iber T; Adler J; Wachter U; Vassilev D; Georgieff M; Vogt J Br J Pharmacol; 1997 Dec; 122(8):1605-10. PubMed ID: 9422804 [TBL] [Abstract][Full Text] [Related]
9. A dose-response study of nitric oxide synthase inhibition in different vascular beds in man. Hjorth Lassen L; Klingenberg Iversen H; Olesen J Eur J Clin Pharmacol; 2003 Oct; 59(7):499-505. PubMed ID: 13680036 [TBL] [Abstract][Full Text] [Related]
10. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. ; Alexander JH; Reynolds HR; Stebbins AL; Dzavik V; Harrington RA; Van de Werf F; Hochman JS JAMA; 2007 Apr; 297(15):1657-66. PubMed ID: 17387132 [TBL] [Abstract][Full Text] [Related]
11. Initial experiences with the Impella device in patients with cardiogenic shock - Impella support for cardiogenic shock. Meyns B; Dens J; Sergeant P; Herijgers P; Daenen W; Flameng W Thorac Cardiovasc Surg; 2003 Dec; 51(6):312-7. PubMed ID: 14669126 [TBL] [Abstract][Full Text] [Related]
12. Prophylactic high-dose N(omega)-monomethyl-L-arginine prevents the late cardiac dysfunction associated with lethal tumor necrosis factor-alpha challenge in dogs. Sevransky J; Vandivier RW; Gerstenberger E; Correa R; Ferantz V; Banks SM; Danner RL; Eichacker PQ; Natanson C Shock; 2005 Mar; 23(3):281-8. PubMed ID: 15718929 [TBL] [Abstract][Full Text] [Related]
13. Nitric oxide synthase inhibition restores orthostatic tolerance in young vasovagal syncope patients. Stewart JM; Sutton R; Kothari ML; Goetz AM; Visintainer P; Medow MS Heart; 2017 Nov; 103(21):1711-1718. PubMed ID: 28501796 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans. Mayer BX; Mensik C; Krishnaswami S; Derendorf H; Eichler HG; Schmetterer L; Wolzt M Br J Clin Pharmacol; 1999 May; 47(5):539-44. PubMed ID: 10336578 [TBL] [Abstract][Full Text] [Related]
15. Assessment of endothelial function of the renal vasculature in human subjects. Delles C; Jacobi J; Schlaich MP; John S; Schmieder RE Am J Hypertens; 2002 Jan; 15(1 Pt 1):3-9. PubMed ID: 11824856 [TBL] [Abstract][Full Text] [Related]
17. Nitric oxide spares myocardial oxygen consumption through attenuation of contractile response to beta-adrenergic stimulation in patients with idiopathic dilated cardiomyopathy. Shinke T; Takaoka H; Takeuchi M; Hata K; Kawai H; Okubo H; Kijima Y; Murata T; Yokoyama M Circulation; 2000 Apr; 101(16):1925-30. PubMed ID: 10779458 [TBL] [Abstract][Full Text] [Related]
18. The effects of Levosimendan on global haemodynamics in patients with cardiogenic shock. Rokyta R; Pechman V Neuro Endocrinol Lett; 2006; 27(1-2):121-7. PubMed ID: 16648778 [TBL] [Abstract][Full Text] [Related]
19. Changes in renal and systemic hemodynamics after NO-synthase inhibition in males with family history of hypertension. Berger ED; Bader BD; Rüb N; Rauscher MA; Rebenschütz I; Gaber OC; Enderle MD; Risler T; Erley CM Kidney Blood Press Res; 2002; 25(1):42-9. PubMed ID: 11834876 [TBL] [Abstract][Full Text] [Related]
20. Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction. Jolly S; Newton G; Horlick E; Seidelin PH; Ross HJ; Husain M; Dzavik V Am J Cardiol; 2005 Dec; 96(12):1617-20. PubMed ID: 16360345 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]